EXEL
Search by
TICKER SYMBOL
TICKER SYMBOL
OptionsHawk Content
Bullish Open Interest Points to Higher for Oncology Name
May 07, 2023
Exelixis (EXEL) shares are bouncing nicely off the rising 21-week EMA the past week after the pullback to long term support found buyers ahead of...
M&A Analysis: Biotech Deals Heat Up in Q2
Jun 19, 2022
Biotech (XBI) M&A heated up in Q2 with several large deals announced or speculated with Neuro and Oncology remaining the top areas Pharma is looking...
Exelixis (EXEL) Bull Wedge Ahead of Key Data
Feb 02, 2022
Exelixis (EXEL) shares hitting the ‘ready to run’ scan today with shares sitting just below the top of February value and a multi-week breakout. A move...
Unusual Bull Flow into Mid-Cap Bio Ahead of Key Early 2022 Catalyst
Dec 20, 2021
Exelixis (EXEL) with Phase 3 data in early 2022 for cabozantinib for the treatment of Hepatocellular Carcinoma. The study focuses on using cabozantinib with atezolizumab...
Biotech Event: Exelixis (EXEL) Set for Key Data in Q2 in Liver Cancer
Mar 16, 2021
Exelixis (EXEL) strong setup with shares starting to work out of a multi-week bull wedge and key data upcoming in Q2 with a Phase 3...
M&A Analysis: Biotech M&A – July 2019
Jul 01, 2019
The Pfizer (PFE) deal for Array (ARRY) was one of the most interesting deals as it came at a strong 60% premium and options activity...